In searching efficacious strategies to target PDGFRβ-positive TNBC in alternative to PDGFRβ tyrosine kinase inhibitors, which showed limited clinical activity in TNBC as single agents and severe side effects [33, 34], we recently tested the Gint4.T nuclease-resistant RNA aptamer, which we previously validated as a high affinity ligand/inhibitor of PDGFRβ in glioblastoma (GBM) [35, 36] and human bone marrow-derived mesenchymal stem cells (BM-MSCs) [22]. Here, PDGFRB is linked to glioblastoma.